Suppression of lymphokine‐activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck
- 1 October 1990
- journal article
- other
- Published by Wiley in Otolaryngology -- Head and Neck Surgery
- Vol. 103 (4), 537-549
- https://doi.org/10.1177/019459989010300404
Abstract
Incubation of human peripheral blood lymphocytes (PBL) in the presence of interleukin-2 results in the generation of lymphokine-activated killer (LAK) cells that are highly cytotoxic to a variety of autologous and allogenic tumor targets. We have identified a noncytotoxic, soluble factor, produced by human squamous cell cancers of the head and neck, that profoundly inhibits the generation of LAK cytotoxicity. Inhibition of the generation of cytotoxicity was demonstrated with coculture of PBL and freshly disaggregated tumor cells in a Transwell two-chamber system. Alternatively, Inhibition occurred when LAK cells were generated in the presence of tumor-conditioned supernatants alone. These effects were not observed with conditioned supernatants from autologous or allogenic lymphocytes, human fibroblasts, or the erythroleukemia cell line K562. The presence of this inhibitory factor(s) was not required during the entire period of LAK generation. Suppression of cytotoxicity, measured after 4 days of LAK generation, could also be demonstrated when the conditioned tumor supernatant was present in only the last 24 hours of incubation. Suppression is mediated by a heat-labile factor with a molecular weight of >75 kd. These results suggest that LAK cytotoxicity may be significantly impaired by soluble immunoregulatory factors present within the tumor milieu of squamous cell carcinomas of the head and neck. Further characterization of these factors may lead to the development of more rational and effective forms of immunotherapy.Keywords
This publication has 11 references indexed in Scilit:
- Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell linesBritish Journal of Cancer, 1989
- New Approaches to the Immunotherapy of Cancer Using Interleukin-2Annals of Internal Medicine, 1988
- Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.Journal of Clinical Oncology, 1988
- Generation of activated killer cells in tumor-bearing hostsInternational Journal of Cancer, 1987
- Miniaturization of the standard 51Cr release assay for long term follow-up of NK activity of individual miceJournal of Immunological Methods, 1986
- Activation of suppressor cells by low molecular weight factors secreted by spleen cells of tumor-bearing mice: Modulatory role of prostaglandinsInternational Journal of Immunopharmacology, 1986
- Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.The Journal of Experimental Medicine, 1981
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Mastocytoma-mediated suppression of mixed lymphocyte culture and mitogen responsivenessCellular Immunology, 1976
- Suppression of the immune response by alpha-fetoprotein on the primary and secondary antibody response.The Journal of Experimental Medicine, 1975